{"description":"Safety set included all participants who received at least 1 dose of any component of the combination therapy.","eventGroups":[{"deathsNumAffected":2,"deathsNumAtRisk":4,"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 500 mg dostarlimab as a 30-minute IV infusion 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles (Q3W).","id":"EG000","otherNumAffected":4,"otherNumAtRisk":4,"seriousNumAffected":2,"seriousNumAtRisk":4,"title":"1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":4,"numEvents":2}],"term":"Thrombocytopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":2}],"term":"Dry eye"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":2}],"term":"Eye irritation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":2}],"term":"Foreign body sensation in eyes"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":4,"numEvents":7}],"term":"Vision blurred"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Diarrhoea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Pyrexia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Alanine aminotransferase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Aspartate aminotransferase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Blood bilirubin increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":3}],"term":"Neutrophil count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Hypokalaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Headache"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Oropharyngeal pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":4,"numEvents":2}],"term":"Productive cough"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Pyrexia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4,"numEvents":2}],"term":"Hypercalcaemia"}],"timeFrame":"All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected maximum up to 153 weeks."}